insulin aspart, insulin aspart protamine drug combination 30:70

AIMS Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of IDeg and IAsp. This pan-Asian, 26-week trial… Expand

OBJECTIVE Insulin degludec/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration of… Expand

AIMS The IMPROVE observational study evaluated the safety profile and effectiveness of biphasic insulin aspart 30/70 (BIAsp 30… Expand

BACKGROUND Insulin is recommended as a second-line treatment after diet and metformin fail to reach and/or maintain glycemic… Expand

Aim: This 3-month study compared the effect on overall glycemic control of adding biphasic insulin aspart 30 (BIAsp30) and… Expand

AIMS The IMPROVE study is a multinational, open-label, non-randomised, 26-week observational study assessing the safety and… Expand

BACKGROUND Modern premixed insulins offer a flexible approach to the initiation of insulin therapy in patients with poorly… Expand

BACKGROUND: In this study, we sought to compare the long-term safety and efficacy of biphasic insulin aspart 30 (BIAsp30) with… Expand

OBJECTIVE Biphasic insulin aspart 30 (BIAsp30) is a dual release formulation, containing 30% soluble and 70% protamine… Expand

AbstractObjective: With the aim to obtain a premixed rapid-acting insulin with a serum insulin profile more closely resembling… Expand